August 2017: Approved by Food and Drug Administration
October 2017: Started Phase Ia clinical trial
November 2017: Interim safety review successfully completed
January-March 2018: Complete injections of second cohort; perform last blood draw; begin one-year follow-up period
June-December 2017: Complete clinical sample processing; analyze data and clinical immunology
January-March 2019: Analyze data and clinical immunology; write clinical study report
August 2019: Completed Phase Ia clinical trial
2019-2021: Two-year Phase Ib clinical trial in Brazil